Showing results (81-90 of 111) with videos related to
Sort By:
Pageof 12
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2012
Serum levels of LIGHT in MSClas Malmeström, Alan Gillett, Margareta Jernås, et al.Neurology|October 21, 2016
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacyJonatan Salzer, Rasmus Svenningsson, Peter Alping, et al.Annals of Neurology|July 25, 2024
Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future DirectionsAntonio Scalfari, Anthony Traboulsee, Jiwon Oh, et al.European Journal of Neurology|July 31, 2023
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapiesMonika Rabenstein, Olivia G Thomas, Giorgia Carlin, et al.JAMA Neurology|October 8, 2019
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesGustavo Luna, Peter Alping, Joachim Burman, et al.Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.Neurology|February 13, 2020
Blood neurofilament light levels segregate treatment effects in multiple sclerosisBénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 21, 2014
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experienceJoachim Burman, Ellen Iacobaeus, Anders Svenningsson, et al.Journal of Neurology, Neurosurgery, and Psychiatry|August 9, 2023
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapyElisa Longinetti, Simon Englund, Joachim Burman, et al.European Journal of Neurology|February 20, 2024
Rituximab treatment in pediatric-onset multiple sclerosisMarkus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, et al.Pageof 12